Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME

AIMS: The EMPA‐REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes with empagliflozin, a sodium–glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes and established CV disease over a study period of 3 years. We aimed to investigate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellicori, Pierpaolo, Ofstad, Anne Pernille, Fitchett, David, Zeller, Cordula, Wanner, Christoph, George, Jyothis, Zinman, Bernard, Brueckmann, Martina, Lindenfeld, JoAnn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754994/
https://www.ncbi.nlm.nih.gov/pubmed/32915523
http://dx.doi.org/10.1002/ehf2.12891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754994/
https://www.ncbi.nlm.nih.gov/pubmed/32915523
http://dx.doi.org/10.1002/ehf2.12891

Ejemplares similares